September 3 (Thu)

09:00-10:30

Satellite Symposium 1
Servier  boryung
Future insight for the management of pancreatic and biliary tract cancers
  1. 1.Optimal continuum of care for metastatic pancreatic adenocarcinoma
  2. 2.Individualizing gemcitabine-based regimens in cholangiocarcinoma
  3. 3.Liposomal irinotecan in metastatic pancreatic cancer: Asian and Korean experiences

11:30-12:10

Satellite Symposium 2
MSD
The current and future challenges: Good luck does not always repeat
  1. 1.Turning hope into reality: We dream for a better tomorrow with Pembrolizumab (1L NSCLC)
  2. 2.Everything comes to those who challenge: What is the best regimen for 1L R/M HNSCC patients?
Satellite Symposium 3
Roche
The beginning of immunotherapy journey in breast cancer
  1. 1.IMpassion 130: The first immune checkpoint inhibitor for 1L mTNBC patient
  2. 2.Overview of current biomarkers in metastatic TNBC
Satellite Symposium 4
Eisai
Lenvatinib treatment in first line uHCC and subsequent treatments
  1. 1.Overseas experience on subsequent treatment after 1st Line Lenvima in uHCC (TBC)
  2. 2.Korean real-world experience of 1st-line Lenvima in advanced HCC

14:40-15:20

Satellite Symposium 5
Amgen
Importance of bone health management in palliative setting
  1. 1.Integrated bone health management in prostate cancer
  2. 2.AI induced bone metastasis in Breast cancer

15:20-16:00

Satellite Symposium 6
menarini
  1. 1.Patient-centred treatment strategies for breakthrough cancer pain
  2. 2.Real world experience sharing from other country

16:20-17:00

Satellite Symposium 7
Sanofi
What is being considered for continuum of care in metastatic colorectal cancer?
  1. 1.Biomarker driven 2nd line treatment for patients with mCRC: Insights in Biomarker
  2. 2.Choosing anti-VEGF agents in 2nd line treatment for mCRC: Korean experience

September 4 (Fri)

08:00-08:40

Satellite Symposium 8
MeRcK
New indication(s) of PD-L1 inhibitor, Bavencio

09:00-09:40

Satellite Symposium 9
Pfizer
New perspectives for treatment naïve patients with EGFR+ non small cell lung cancer
  1. 1.Treatment for EGFR+ NSCLC: Where are we now?
  2. 2.Optimal treatment sequence in EGFR+ non-small cell lung cancer

10:50-11:30

Satellite Symposium 10
Lilly
Continuing Advances in metastatic Breast Cancer: How to make optimal treatment decision for metastatic breast cancer patients
  1. 1.Role of prognostic factor in treatment choice for HR+, HER2- metastatic breast cancer patients
  2. 2.Continuing advances in metastatic breast cancer: Clinical overview of Abemaciclib
Satellite Symposium 11
Takeda
Treatment options for patients with ALK+ NSCLC: How is the paradigm changing?
  1. 1.Long-term survival for patients with ALK+ NSCLC: An achievable aim?
  2. 2.New Standards of Care in post crizotinib ALK+NSCLC: Roles of brigatinib in optimal sequential treatments

11:30-12:10

Satellite Symposium 12
ONO/BMS
Ever forward with cancer immunotherapy: the progress so far and new frontiers
  1. 1.Optimal Therapeutic Strategies for Esophageal cancer
  2. 2.Big Journey of Immunotherapy for NSCLC in Korea
Satellite Symposium 13
BAYER
From concept to practice - new era of precision medicine
Larotrecitinb, “The REAL DRUG” for TRK fusion cancer patients

16:20-17:00

Satellite Symposium 14
Daewoong  Samsung Bioepis
Building confidence in Biosimilars: From data to patient